GLP-1 receptor agonists were associated with reduced risk of alcohol, cannabis, cocaine, nicotine and opioid use disorders, as well as other substance use disorders, suggesting potential prevention effects across a broad range of substances, according to a study published March 4 in The BMJ.
Researchers from the VA St. Louis Health Care System and Washington University in St. Louis analyzed EHR data from 606,434 veterans over up to three years, comparing GLP-1 receptor agonists with SGLT-2 inhibitors. Seven trials were included for each incident SUD outcome, and one trial was included for adverse outcomes in individuals with preexisting substance use disorder.
Previous observational studies have linked GLP-1 receptor agonist use to lower risk of incident and recurrent alcohol, tobacco and cannabis use disorders.
Here are three things to know:
- Patients taking GLP-1 receptor agonists had a lower risk of the composite outcome for all substance use disorders.
- Among patients with preexisting substance use disorder, GLP-1 receptor agonists were associated with lower risk of emergency department visits, hospitalization admission and mortality.
- Use of GLP-1 receptor agonists was associated with lower risks of drug overdose and suicidal ideation or attempts.
At the Becker's Fall Behavioral Health Summit, taking place November 4–5 in Chicago, behavioral health leaders and executives will explore strategies for expanding access to care, integrating services, addressing workforce challenges and leveraging innovation to improve outcomes across the behavioral health continuum. Apply for complimentary registration now.
